A 64-year-old man with hypertension has been taking Telmisartan for three months. During a follow-up visit, routine blood tests reveal an electrolyte abnormality, although his kidney function remains stable.
Question:
Which electrolyte abnormality is most likely associated with Telmisartan?
MBH/PS
Telmisartan is an angiotensin II receptor blocker (ARB). It reduces aldosterone secretion, leading to decreased potassium excretion by the kidneys, which can result in hyperkalemia, especially in patients with kidney disease or those taking potassium supplements or potassium-sparing diuretics.
Daily studying and knowing about one drug improves knowledge and it is easy to remember for students
Ace inhibitors and ARBs can both lead to Hyperkalemia, dry cough and angioedema
Hyperkalemia is caused by telmisartan use,bas the medicine can cause increased potassium loss through urine. The medicine works by modulating renin-angiotensin-aldosterone system (RAAS) pathway, and may cause hyperkalemia.
Telmisartan is an ARB which works by inhibiting aldosterone secretion. Aldosterone naturally promotes sodium reabsorption and potassium excretion in kidneys, suppressing aldosterone reduces potassium excretion which directly lead to elevated serum potassium level.
It is observed that Telmisartan reduces aldosterone levels, causing the kidneys to excrete less potassium, which can lead to elevated serum potassium.